[Therapeutic effects of Tiaozhong Granule on esophagus mucous membrane in rats with mixed reflux esophagitis and the mechanisms].
OBJECTIVE
To explore the mechanism of Tiaozhong Granule (TZG), a compound traditional Chinese herbal medicine, in treating rats with mixed reflux esophagitis.


METHODS
Fifty-eight SD rats were randomly divided into untreated group (n=12), sham-operated group (n=10), TZG-treated group (n=12), Banxia Xiexin Decoction (BXXXD)-treated group (n=12) and cisapride-treated group (n=12). Mixed reflux esophagitis was induced by esophago-duodenum end-to-side anastomosis. Four weeks later, the rats were orally administered twice daily for 12 days. Pathological changes of esophagus mucous membrane were observed by using HE staining. The expressions of proliferating cell nuclear antigen (PCNA) and p53 in the esophagus tissue were detected by immunohistochemical SABC method. Spectrophotometric method was used to detect the content of malondialdehyde (MDA) and the activities of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in serum.


RESULTS
Compared with the untreated group, pathological changes of esophagus mucous membrane were relieved in different degrees in TZG-treated group, BXXXD-treated group and cisapride-treated group. Content of MDA and expressions of PCNA and p53 were obviously decreased in the three treated groups (P<0.01), and the activities of SOD and GSH-Px were significantly increased in the three treated groups (P<0.05, P<0.01). TZG had better effects than cisapride in decreasing the content of MDA and increasing the activities of SOD and GSH-Px (P<0.05). TZG was better in aspect of reducing the expressions of PCNA and p53 than BXXXD and cisapride tablets (P<0.05).


CONCLUSIONS
Tiaozhong Granule can treat mixed reflux esophagitis in rats, and its action mechanisms may be associated with decreasing the expressions of PCNA and p53 in esophagus mucous membrane, reducing the content of MDA and increasing the activities of SOD and GSH-Px in serum.
Shi
Zhao-hong
ZH
Department of Gastroenterology, Wuhan No. 1 Hospital, Wuhan, Hubei Province 430022, China. ycfyx2000@126.com
Su
Wen
W
Zhang
Jie-mei
JM
Hao
Jian-jun
JJ
Feng
Yun-xia
YX
Chen
Zhou
Z
D000818:Animals; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004942:Esophagitis, Peptic / Q000188:drug therapy*; D004947:Esophagus / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D008297:Male; D009092:Mucous Membrane / Q000187:drug effects* / Q000378:metabolism; D008517:Phytotherapy; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013482:Superoxide Dismutase / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D004365:Drugs, Chinese Herbal; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; D013482:Superoxide Dismutase